Newsfeeds Archive - Page 4 of 4

5 minute read

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session

December 13, 1:14 PM

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

ACMR

1 minute read

Corvus Pharmaceuticals Presents Updated Data From CPI-818 Phase 1/1b Clinical Trial At The 64th American Society Of Hematology Annual Meeting & Exposition

By Benzinga Newsdesk

December 12, 11:03 AM

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and

CRVS

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

November 3, 5:42 AM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

AAOI

1 minute read

Earnings

Earnings Preview For Corvus Pharmaceuticals

By Benzinga Insights

November 2, 11:14 AM

Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Corvus Pharmaceuticals will report an earnings per share (EPS) of $-0.16.

CRVS

21 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

September 28, 12:40 PM

Wednesday's session saw 361 companies set new 52-week lows.

2 minute read

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1b Clinical Trial Of Mupadolimab In China

By Benzinga Newsdesk

September 26, 4:13 PM

BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate

CRVS

1 minute read

Earnings

Corvus Pharmaceuticals: Q2 Earnings Insights

By Benzinga Insights

August 8, 11:39 PM

Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

CRVS